A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

Non Small Cell Lung Cancer Clinical Trial

— LUNGadenosine  

Official title:

Assessing the Expression of A2R Receptors and CD39 and CD73 Ectonucleotidases on Circulating Tumour Cells of Non-small Cell Lung Carcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05648188
• Other study ID #: 22Pneumo01
• Status: Not yet recruiting
• Start date: January 1, 2023
• Est. completion date: October 30, 2024

Study information

• Verified date: December 2022
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Jonathan BENZAQUEN, Dr
• Phone: 492038052
• Email: benzaquen.j[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: October 30, 2024
• Est. primary completion date: October 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

i) Inclusion criteria:

• Patient of legal age (>18 years), any gender,

• operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC)

ii) Exclusion criteria:

• Patient with any other active cancer.

• Lack of evaluable material.

Related Conditions & MeSH terms

• Lung Neoplasms
• Neoplastic Cells, Circulating
• Non Small Cell Lung Cancer

Intervention

Biological:
• Sample
Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ex vivo expression of A2R (adenosine receptor), CD39, CD73 and P2RX7 on NSCLC and CTC	Presence versus Absence of expression (immunohistochemistry)	At inclusion
Secondary	In vitro impact of radiation therapy on the A2R, CD39, CD73 expression by cells lineage	Upregulation / Downregulation of expression (mRNA by real time PCR)	At inclusion